Tsefpirom - instructions for use, dose, side effects, contraindications

Clinical and pharmacological group: & nbsp

Cephalosporins

Included in the formulation

Isodep®

powder w / m in / in

Cephanorm

powdersolution w / m in / in

Simpex Pharma Pvt Ltd. India

Tsefpyroma sulfate and sodium carbonate

АТХ:

J.01.D.E.02 Tsefpyrom

Pharmacodynamics:

Antibiotic group cephalosporins of the IV generation. Has bactericidal action due to inhibition of bacterial cell wall synthesis. Violates the synthesis of the biopolymer peptidoglikana - the main component of the cell wall of bacteria. It inhibits the peptidoglycan transpeptidase, inhibits the activity of the endogenous inhibitor, which leads to activation of murein hydrolase, which cleaves peptidoglycan. Effective against fissile bacteria, in the walls of which the synthesis of peptidoglycan occurs.

Has a wide spectrum of action against gram-positive and gram-negative bacteria, strains resistant to cephalosporin antibiotics of the third generation and aminoglycosides. Active with respect to E. coli, Salmonella spp., Shigella spp., Proteus mirabilis, Proteus vulgaris, Providencia, Morganella morganii, Citrobacter diversus, Citrobacter freundii, Klebsiella oxytoca, Serratia spp., Enterobacter spp., Haemophilus influenzae, Neisseria spp., Moraxella catarrhalis, Streptococcus spp., Staphylococcus spp., Peptostreptococcus spp., Clostridium perfringens, Ps. aeruginosa.

Pharmacokinetics:

After intravenous administration, the maximum concentration in the blood plasma is reached after 5 minutes. The connection with plasma proteins is about 10%.

Penetrates into all organs and tissues. When meningitis gets into the cerebrospinal fluid.It is subject to partial metabolism in the liver. Do not cumulate. Penetrates through the placental barrier, is found in breast milk.

The elimination half-life is 2 hours. Elimination by the kidneys.

Indications:

It is used to treat infections caused by susceptible microorganisms cefpirome, including in patients with neutropenia and immunocompromised: septicemia, bacteremia, complicated infections of the upper and lower parts of the urinary system, pneumonia, lung abscess, empyema, skin and soft tissue infections.

ICD-10

I.A30-A49.A40 Streptococcal septicemia

I.A30-A49.A41 Other septicemia

X.J10-J18.J15 Bacterial pneumonia, not elsewhere classified

X.J20-J22.J20 Acute bronchitis

X.J40-J47.J42 Chronic bronchitis, unspecified

X.J40-J47.J40 Bronchitis, not specified as acute or chronic

X.J85-J86.J85 Abscess of the lung and mediastinum

X.J85-J86.J86 Pythothrace

X.J90-J94.J90 Pleural effusion, not elsewhere classified

XII.L00-L08.L01 Impetigo

XII.L00-L08.L02 Abscess of skin, boil and carbuncle

XII.L00-L08.L03 Phlegmon

XII.L00-L08.L08.0 Pyoderma

XIV.N10-N16.N11 Chronic tubulointerstitial nephritis

XIV.N10-N16.N10 Acute tubulointerstitial nephritis

XIV.N30-N39.N30 Cystitis

XIV.N30-N39.N34 Urethritis and urethral syndrome

XIV.N40-N51.N41 Inflammatory diseases of the prostate

XIV.N70-N77.N70 Salpingitis and oophoritis

XIV.N70-N77.N71.0 Acute inflammatory disease of the uterus

XIV.N70-N77.N72 Inflammatory disease of the cervix

XIV.N70-N77.N73.0 Acute parametritis and pelvic cellulite

XIV.N70-N77.N75 Diseases of the Bartholin gland

XXI.Z20-Z29.Z29.2 Another type of preventive chemotherapy

Contraindications:

Individual intolerance of β-lactam antibiotics: penicillins and cephalosporins, children under 12 years.

Carefully:

Imbalance of electrolytes or fluids, severe liver damage, colitis in history.

Pregnancy and lactation:

Recommendations for FDA - Category B. It is used with caution during pregnancy and lactation in cases where the intended benefit exceeds the risk to the fetus and newborn.

Dosing and Administration:

Intravenously struino, slowly or infuzionno, 1-2 g every 12 hours. Patients on hemodialysis receive 500 mg per day with an additional 250 mg after each procedure.

The highest daily dose: 2 g.

The highest single dose: 2 g.

Side effects:

Central and peripheral nervous system: rarely - convulsions.

Hemopoietic system: thrombocytopenia, eosinophilia, leukopenia, an increase in prothrombin index and coagulation time.

Digestive system: nausea, vomiting, diarrhea, increased activity of hepatic enzymes, hepatic or cholestatic jaundice, intestinal dysbacteriosis.

Dermatological reactions: local reactions - compaction at the injection site, candidiasis dermatitis, vulvovaginitis.

urinary system: rarely - the development of hypokalemia.

Allergic reactions.

Overdose:

Convulsions, tremor, increased neuromuscular excitability, encephalopathy (especially with renal failure).

Treatment: hemodialysis (within 4 hours is eliminated 40-45%) and symptomatic treatment.

Interaction:

Simultaneous application with probenecid slows the renal excretion of cefpirom.

"Loop diuretics" block the tubular secretion of ceftirom.

Special instructions:

Ceftir is not recommended for the treatment of meningitis.

Simultaneous use with ethanol can cause a disulfiram-like reaction.

Instructions

Tsefpyrom (Cefpiromum)